CompletedPhase 2

Safety and Efficacy of AIN457 in Noninfectious Uveitis

United States76 participantsStarted 2008-06

Plain-language summary

This study was performed to evaluate the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * Active uveitis (i.e., uveitis that is not in remission). * Intermediate uveitis, posterior uveitis, or panuveitis must be sufficiently severe that systemic immunosuppression is indicated. Exclusion criteria: * Active infection. * Weight must not be greater that 120kg. Other protocol-defined inclusion/exclusion criteria may apply

What they're measuring

Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Who Died

Timeframe: Day 1 to Day 603

Trial details

NCT IDNCT00685399

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2013-09

Results submitted2015-02-12

View on ClinicalTrials.gov More Non-infectious Uveitis trials